stoxline Quote Chart Rank Option Currency Glossary
Contineum Therapeutics, Inc. Class A Common Stock (CTNM)
15.76  -0.35 (-2.17%)    05-24 16:00
Open: 16
High: 16.05
Volume: 29,018
Pre. Close: 16.11
Low: 15.38
Market Cap: 405(M)
Technical analysis
2024-05-24 4:52:05 PM
Short term     
Mid term     
Targets 6-month :  19.16 1-year :  22.38
Resists First :  16.4 Second :  19.16
Pivot price 15.55
Supports First :  14.46 Second :  13.27
MAs MA(5) :  15.88 MA(20) :  15.46
MA(100) :  0 MA(250) :  0
MACD MACD :  0.1 Signal :  0
%K %D K(14,3) :  87.3 D(3) :  90.8
RSI RSI(14): 52.7
52-week High :  16.4 Low :  13.27
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ CTNM ] has closed below upper band by 37.3%. Bollinger Bands are 0% narrower than normal.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 16.07 - 16.15 16.15 - 16.22
Low: 15.2 - 15.28 15.28 - 15.35
Close: 15.64 - 15.77 15.77 - 15.88
Company Description

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.

Headline News

Mon, 20 May 2024
Contineum Therapeutics Announces Appointment of Troy Ignelzi to Board of Directors - Manchestertimes

Thu, 16 May 2024
Contineum Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights - Business Wire

Fri, 05 Apr 2024
Contineum Therapeutics Inc. - BioWorld Online

Fri, 05 Apr 2024
Gunderson, Sidley Steer Biotech's Scaled-Down $110M IPO - Law360

Fri, 05 Apr 2024
Contineum prices $110M IPO to advance LPA1R antagonists - BioWorld Online

Wed, 03 Apr 2024
Contineum Therapeutics Finalizes $150 Million IPO Terms (NASDAQ:CTNM) - Seeking Alpha

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 23 (M)
Shares Float 2 (M)
Held by Insiders 8.6 (%)
Held by Institutions 47.2 (%)
Shares Short 523 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 45.4 %
Operating Margin 32.1 %
Return on Assets (ttm) 11.1 %
Return on Equity (ttm) 27.7 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 2.13
EBITDA (p.s.) 0.69
Qtrly Earnings Growth 0 %
Operating Cash Flow 19 (M)
Levered Free Cash Flow 13 (M)
Stock Valuations
PE Ratio 0
PEG Ratio 0
Price to Book value 0
Price to Sales 7.37
Price to Cash Flow 19.05
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android